{"entity":{"id":"paper-innovatv-301-tisotumab-nejm-2024","kind":"paper","name":"innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer","aka":[],"tldr":"The tissue factor-directed antibody-drug conjugate tisotumab vedotin lengthened survival compared with chemotherapy in cervical cancer that had progressed after first-line treatment, at the cost of eye and nerve side effects.","summary":"Phase 3 trial of 502 patients with recurrent or metastatic cervical cancer after one or two prior systemic regimens randomised to tisotumab vedotin or investigator's choice chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed).\n\nMedian overall survival was 11.5 versus 9.5 months (hazard ratio 0.70), progression-free survival 4.2 versus 2.9 months and objective response 17.8 versus 5.2 percent; ocular events, peripheral neuropathy and bleeding were the characteristic toxicities.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2024","url":"https://doi.org/10.1056/NEJMoa2313811"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38959480/"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tisotumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["innovatv-301"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/NEJMoa2313811","pmid":"38959480","authors":"Vergote I, González-Martín A, Fujiwara K, et al.","paperType":"rct","findings":["Median overall survival 11.5 vs 9.5 months; hazard ratio 0.70.","Objective response 17.8 percent vs 5.2 percent."],"whatItMeans":"Tisotumab vedotin is the standard second-line treatment for recurrent cervical cancer after chemo-immunotherapy, with a mandatory eye-care protocol.","caveats":["Modest absolute gains.","Conjunctivitis and keratitis require prophylactic eye drops and regular examinations."],"changedPractice":true,"participants":502},"route":"/key-papers/paper-innovatv-301-tisotumab-nejm-2024/","neighbours":{"cancer":[{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"drug":[{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"}],"trial":[{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}